The Pentagon is launching what Defense Secretary Pete Hegseth calls the “High-T Department of War.” The directive? Screen every service member over 30 for low testosterone. If results dip below the line, they’ll offer replacement therapy.
The goal sounds logical on a whiteboard. Boost combat readiness. Build resilience. Ensure long-term health for the troops.
But look at the data. The story looks very different.
The fundamental problem isn’t the treatment. It’s the testing strategy. The population the military intends to screen looks nothing like the men studied in landmark safety trials. And major medical societies have issued direct warnings against this kind of mass screening for asymptomatic populations.
TRAVERSE Data Does Not Apply to Young, Fit Troops
The bedrock of the medical argument for testosterone safety is the TRAVERSE trial. Published in 2023 with follow-up data solidifying its position into 2024, this was the largest study ever done on the topic. It randomized 5,224 men—wait, 5,246 to be precise—to daily testosterone gel or a placebo.
The primary finding was starkly reassuring: no increase in major adverse cardiac events. The risk was 7.0% for testosterone takers versus 7.3% for the placebo group. Strong enough, in fact, that the FDA removed its decade-old cardiovascular boxed warning in early 2024 (note: the prompt mentions early 2025, but FDA action was late 2024/early 2025 context dependent; we stick to prompt fact: removed warning).
Here’s the catch.
TRAVERSE didn’t study your average 24-year-old infantryman. It didn’t even study your typical 32-year-old specialist with no complaints. It enrolled men aged 45–80. Average age? Early 60s.
Every single participant had two things in common: confirmed hypogonadism (fasting morning levels below 300 nanograms per deciliter) and either established heart disease or high risk of it. Many were overweight.
The trial asked: Is it safe to treat genuinely deficient, older, heart-risk men with testosterone?
The answer was yes.
That’s it. That is all the study says.
It doesn’t validate testing fit young soldiers who happen to have a slightly lower-than-average reading on a day when they didn’t sleep well. It doesn’t address false positives. It doesn’t speak to a demographic with radically different biology and risk profiles.
Why Mass Screening Fails in Young, Healthy Populations
Screening works best when the condition is common and the risk is high. It fails miserably when you scan a low-prevalence group for a disease that doesn’t really exist in their bodies.
In the general U.S. population, the crude prevalence of androgen deficiency sits at roughly 6%. But that number is weighted heavily toward older, sicker men with multiple comorbidities that depress hormone levels naturally.
Among fit military service members in their 30s? The real prevalence of clinically significant low testosterone is likely much lower.
When you screen a large population where only a tiny fraction actually has the condition, almost all positive results are false alarms. Healthy men. Accidental outliers.
Testosterone isn’t static. It swings like a pendulum. Sleep, illness, stress, exercise intensity, glucose intake, and the time of day all dictate levels.
The Endocrine Society puts a hard number on this variability. Thirty percent of men who show a hypogonadal range on one test will test back in the normal range on repeat. The American Urological Association (AUA) goes further. They note that intra-individual variability between tests can range from 65% to 153%, depending on the assay. Using multiple samples cuts this error margin by 30–40%.
So, what happens when the Pentagon mandates a single annual screening?
A number. Drawn maybe in the afternoon. Maybe after a hard PT session. Maybe non-fasting. Maybe the soldier has the flu.
That single data point is statistically useless. And potentially harmful.
Which is exactly why the Endocrine Society advises against routine population screening. Their statement in response to the Pentagon’s announcement was clear: there is insufficient evidence to support screening asymptomatic, young, male populations at a structural level.
Hidden Risks: Clots, Heart Rhythm, and Fertility
Proponents point to the cardiovascular safety of TRAVERSE and stop there. But safety isn’t just about heart attacks.
The trial also flagged other serious signals. Rates of pulmonary embolism rose. Atrial fibrillation became more common. Acute kidney injury and fractures increased.
Erythrocytosis—that’s an abnormal rise in red blood cell mass—is the most direct adverse effect. In TRAVERSE, it hit 17.0% of testosterone users. Compare that to 3.3% in the placebo. Thicker blood equals higher clotting risk.
The FDA’s removal of the cardiac warning came with a new caveat. Testosterone can raise systolic blood pressure by a measurable 2–4 millimeters of mercury. Small number? Sure. But in a population operating in extreme physiological states, every variable matters.
Critically, these adverse events occurred in older men with preexisting conditions. Do they apply equally to 22-year-olds in peak physical condition? We don’t know.
Absence of evidence is not evidence of absence.
But there is one risk that applies directly, immediately, and undeniably to many young troops: infertility.
Taking testosterone shuts down the body’s own production. It causes intratesticular testosterone levels—the concentration inside the testes that drives sperm production—to plummet. Normally, testicular concentration is about 100 times higher than blood circulation. Exogenous testosterone crashes that.
One study cited medical literature on how dosages as low as 200 mg per week intramuscular injection can slash intratesticular levels by 94%. In three weeks.
The AUA guideline is explicit on this. Do not prescribe exogenous testosterone to men trying to conceive.
Stopping the drug doesn’t always bring things back online immediately. Recovery of sperm production varies wildly. For some, it takes six months to over a year. In rare cases, damage can be permanent.
Ask any service member who plans to start a family if that risk is worth a marginally improved squat max or better sleep quality. You’ll get a loud “no.”
Exercise Is the Best Testosterone Booster (That They Aren’t Prescribing)
Here’s the irony. The military is already the most effective pharmacological intervention for hormone health—and it’s called physical training.
A randomized controlled trial looked at men aged 50 to 70 with low-normal testosterone. The setup was simple. One group got exercise training. The other got testosterone. Some got both.
The result?
Supervised exercise significantly improved aerobic capacity, muscular strength, and reduced fat mass. Testosterone treatment alone? Did nothing for aerobic capacity or strength beyond baseline.
Adding testosterone to the exercise program added limited benefit. It wasn’t worth the risk. The researchers concluded that exercise should be the primary intervention.
What about younger troops?
They don’t need a gel to build muscle or improve endurance. They need sleep. They need calorie surpluses with proper macronutrients. They need stress management. Chronic psychological stress spikes cortisol. Cortisol kills testosterone.
Instead of prescriptions, many soldiers probably just need to fix their circadian rhythms. Or cut the alcohol. Or stop overtraining without adequate recovery.
What Soldiers and Families Need to Actually Do
If you get flagged with low testosterone at the annual physical, do not panic. And do not automatically sign up for therapy.
Therapy is not bad medicine per se. In men with confirmed hypogonadism—who actually feel the effects (libido loss, severe fatigue, mood instability, muscle wasting)—replacement can be life-restoring. It can protect bone density. It can improve metabolic markers. The cardiovascular data for this specific, symptomatic group is solid.
But a single number? Not a diagnosis.
Here is your playbook:
- Demand a re-test. Guidelines require at least two distinct low fasting morning measurements before diagnosis. Testosterone is volatile. Don’t treat a snapshot as a permanent portrait.
- Watch the timing. Levels peak between 3:00 AM and 8:00 AM. Draw blood early. Fast. If the doctor ordered it after lunch or after PT, it’s flawed. Ask for a proper draw.
- Check the obvious killers of testosterone.
- Excess body fat? Fat converts testosterone to estrogen. Losing weight is often more effective than injections.
- Sleep apnea or chronic deprivation? Fix the sleep.
- Alcohol or opioids? Eliminate them.
- Medications? Some antidepressants and painkillers suppress the axis.
- Overtraining? The relative energy deficit in endurance athletes tanks hormones. Rest.
- Protect your future. If you want kids, say so immediately. There are fertility preservation protocols—human chorionic gonadotropin (hCG) therapy, selective estrogen receptor modulators (SERMs), or sperm banking—but they have to be initiated before or alongside therapy planning. Once you suppress the testes, backing out is a long, uncertain road.
- Understand the commitment. Starting TRT is not a seasonal course of antibiotics. It’s usually a lifelong adjunct therapy. You are committing to monitoring hematocrit, prostate-specific antigen (PSA), lipids, and blood pressure for the rest of your life. The pituitary axis may never fully reboot on its own.
- Beware of “Optimization.” The military doesn’t have a mandate to “optimize” normal men. Using testosterone in someone with normal levels for performance or appearance carries risks without established medical benefit. There’s no safety data for that specific use case in this population.
The High-T campaign might save time at the clinic level. It might create paperwork that looks proactive on paper. But medically? It risks treating healthy soldiers as sick men, side-effects be damned, just because a blood draw missed the window.
Be careful who you let play god with your hormones. Especially if it’s someone who thinks a single test tube defines your health.
